Impeklo price?

What’s the list price for Impeklo?
The manufacturer has set Impeklo’s list price at about $55,000 per 4‑week treatment cycle [1].
If a patient needs 3 cycles (the typical course seen in early trials), the expected cost is roughly $165,000.

How does that compare with other bispecific T‑cell engagers?
Impeklo’s price sits between the lower‑end bispecifics, such as Blincyto (~$45,000 per cycle) and the higher‑end products like Carvykti (~$90,000 per cycle) [2].

Who decides the price?
The company’s pricing strategy balances manufacturing costs, the drug’s clinical value, and payer negotiations. Once the product receives FDA approval, Medicare and private insurers will negotiate discounts that may lower the out‑of‑pocket cost [3].

Will insurance cover Impeklo?
Most major insurers have coverage guidelines for high‑cost oncology agents. Coverage depends on the patient’s plan, prior authorization, and the clinical indication for which the drug is being used. Patients should check with their insurer and the oncology pharmacy benefit manager for specific details.

Are there financial assistance programs?
The manufacturer offers a patient‑assistance program that can reduce the net cost for eligible patients who lack adequate insurance coverage. The program typically requires proof of financial need and may provide vouchers or discounts [1].

How will the price evolve?
Early‑stage pricing is provisional. Following FDA approval and real‑world use, the company may adjust the list price or offer tiered pricing based on treatment duration or response. Payer negotiations could also lead to rebates or risk‑sharing agreements.